Synonyms: PBI 0451 | PBI0451
Compound class:
Synthetic organic
Comment: Pomotrelvir (PBI-0451; Pardes Biosciences) is an orally administered SARS-CoV-2 Mpro competitive inhibitor [1]. It exhibits antiviral activity against a range of known SARS-CoV-2 variants in vitro.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Pomotrelvir inhibits Mpro proteins from a range of human coronaviruses, including MERS-CoV, SARS-CoV and SARS-CoV-2 [1]. It retains activity against Mpro from the SARS-CoV-2 omicron variant, and is highly selective for the viral Mpro compared to host proteases. |
Selectivity at other protein targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|